Repligen：收购将增加细胞治疗能力 (NASDAQ:RGEN)
· seekingalpha.com
Repligen 以 15 亿美元收购 BioLife 及其强劲的第二季度财报提升了业绩指引，但估值似乎过高。点击查看更多关于 RGEN 股票的信息。
If you like to see more ideas, please subscribe to the Investing Group "Value in Corporate Events" here and try the free trial. In this service we cover major e...